The CD4-like molecule LAG-3, biology and therapeutic applications

Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation

(2014) C. Casati et al.   JOURNAL OF IMMUNOLOGY

Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II

(2014) Bitao Liang et al.   JOURNAL OF IMMUNOLOGY

Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4

(2010) Seng-Ryong Woo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites

(2010) C. Camisaschi et al.   JOURNAL OF IMMUNOLOGY

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

(2010) Chrystelle Brignone et al.   Journal of Translational Medicine

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

(2010) Junko Matsuzaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mycobacterium tuberculosis Peptides Presented by HLA-E Molecules Are Targets for Human CD8+ T-Cells with Cytotoxic as well as Regulatory Activity

(2010) Simone A. Joosten et al.   PLoS Pathogens

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists

(2009) K. S. Peggs et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

(2009) C. Brignone et al.   CLINICAL CANCER RESEARCH

The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses

(2009) Alison Crawford et al.   CURRENT OPINION IN IMMUNOLOGY

Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections

(2009) Tsvetelina Pentcheva-Hoang et al.   IMMUNOLOGICAL REVIEWS

On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection

(2009) Kirsten Richter et al.   INTERNATIONAL IMMUNOLOGY

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells

(2009) J. F. Grosso et al.   JOURNAL OF IMMUNOLOGY

LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis

(2009) C. J. Workman et al.   JOURNAL OF IMMUNOLOGY

Editorial: Therapeutic potential of targeting BTLA

(2009) Alison Crawford et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2

(2009) T. Okamura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lymphocyte Activation Gene-3 Fusion Protein Increases the Potency of a Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy

(2008) B. Li et al.   CLINICAL CANCER RESEARCH

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY